TNBC is characterized as a breast cancer phenotype that is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and is without the overexpression of human epidermal growth factor receptor 2 (HER2), and hence is called the “triple-negative” phenotype2. This evidence concerns the gene ERBB2 and breast cancer.